Buchang Pharma expands product line with Angong Niuhuang Wan technology acquisition

Shandong Buchang Pharmaceuticals has completed the transfer of Angong Niuhuang Wan drug production technology and its manufacturing site, initially acquired from Liaoning Hancaotang Traditional Chinese Medicine Co., Ltd. The product, with approval number Z21021982, will now be manufactured at Buchang Pharma's facility in Heze, Shandong, with the change officially registered on November 18, 2025. This acquisition, for a total of 8.4 million yuan, allows Buchang Pharma to expand its product offerings, with Angong Niuhuang Wan sales projected at 268.94 million yuan in 2024.

In a separate development, Buchang Pharma has provided guarantees totaling 156 million yuan for two of its subsidiaries: Shanghai Hapu Medical Technology Co., Ltd. and Shanghai Hapu Medical Devices Co., Ltd. These guarantees, for 130 million yuan and 26 million yuan respectively, are within the previously approved financing limits and are designed to support the subsidiaries' operational and development needs. The total guarantees provided by the company and its controlled subsidiaries amount to 221,630.79 yuan, representing 21.69% of the audited net assets as of the end of 2024.